BioAtla

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key metrics due to an unexpected $6.5M licensing revenue recognition. Revenue reached $6.5M vs. an expected $0.0M, while GAAP EPS was $0.27 compared to a projected loss of -$8.50. The outperformance was driven by the Context Amendment fee, alongside aggressive cost-cutting measures, including a 70% workforce reduction in March 2026. Despite the quarterly profit, management highlighted substantial doubt about the company's ability to continue as a going concern given a low cash balance of $1.5M.